B-Cell Non-Hodgkin’s Lymphoma (NHL)
Lymphoma is a cancer of the lymphatic system, which is part of the body’s immune system.
What Is Non-Hodgkin’s Lymphoma (NHL)?
The cancer starts in cells called lymphocytes, which are white blood cells that help the body fight off infections. The two main types of lymphocytes are B cells and T cells.
7
Non-Hodgkin’s Lymphoma (NHL) is the seventh most prevalent cancer in the US.
9
NHL has the ninth highest estimated deaths among cancers in the US.
544,352
Estimated people worldwide were diagnosed with NHL in 2021.
Most NHLs are derived from B cells. There are more than 80 subtypes of B-cell NHL.
Diffuse large B-cell lymphoma (DLBCL) is the most common and an aggressive type of non-Hodgkin lymphoma, accounting for about 1 out of every 3 lymphomas.
Who does it affect?
Non-Hodgkin lymphoma (NHL) is a common type of cancer in the United States, accounting for about 4% of all cancers. It’s estimated about 80,620 people (44,590 males and 36,030 females) will be diagnosed with NHL in 2024, including both adults and children.
NHL can occur at any age. In fact, it is one of the more common cancers among children, teens, and young adults. Still, the risk of developing NHL increases throughout life, and more than half of people are 65 or older when they are first diagnosed.
CD19 and its role in B-Cell NHL
CD19 is a protein biomarker found on the surface of mature B cells, a type of white blood cell crucial for the immune system. It plays a significant role in B-cell activation and survival.
In NHL, almost all cancer cells express CD19 on their surface, making it an ideal therapeutic target for this cancer.
